Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm Announces AU$26 Million Funding Facility

Key Highlights 

  • AU$4,000,000 initial funding
  • Equity placement component of up to additional AU$22,000,000 in ordinary shares over 12 month
  • Flexible funding package leading up to a proposed U.S. Listing
SYDNEY, July 19 2019: Noxopharm Ltd (‘Noxopharm’ or the ‘Company’) (ASX:NOX) in recent months has released interim clinical data from both its DARRT-1 and LuPIN studies with both showing encouraging evidence that its immuno-oncology drug candidate, Veyonda?, is providing meaningful anti-cancer responses in men with advanced, progressive prostate cancer (metastatic castration-resistant cancer). That data, along with the recent confirmation of the immuno-oncology drug effects of Veyonda?, supports the Company’s belief that Veyonda? represents a highly promising, new class of anti-cancer therapy.

For further information please download the attached PDF: Download this document